Works best
Taxane-based regimens
Paclitaxel, docetaxel with carboplatin and similar combinations: 63 to 83 per cent success across the pivotal trials, and 78 per cent in the Dutch registry.
What can and cannot be done
Can chemotherapy hair loss be prevented?
Not reliably — but the odds can be shifted a long way, and how far depends almost entirely on which drugs you are having. Here is what scalp cooling actually achieves, with the trial numbers, and what does not work however often you are told it does.
- The two pivotal randomised trials, with their real success rates
- Which regimens scalp cooling suits, and which it does not
- Reviewed by a CION consultant medical oncologist
Ask our chemotherapy team
One of our oncology nurses calls you back. No charge, no obligation.
Medically reviewed by Dr. Naresh Gundu
Consultant Medical Oncologist · MBBS, DNB, DM (Medical Oncology) · last reviewed September 2026, next review due September 2027
The short answer
The short answer
Not completely, and nobody should promise you otherwise. Scalp cooling is the only method with randomised-trial evidence behind it. In the two pivotal trials it kept at least half the hair in 50 to 66 per cent of patients, against 0 per cent of those not cooled — a real difference, and still not a guarantee.
How well it works depends mostly on your regimen: strong with taxanes, weak with anthracyclines, and not shown to work at all when the two are combined. Minoxidil, vitamin E, calcitriol and the rest have not been shown to prevent hair loss, whatever you may read.
What the trials actually showed
50.5% vs 0%
In the SCALP trial, 48 of 95 women using scalp cooling kept at least half their hair, against none of the 47 women who did not — a 50.5 percentage-point difference. The trial was stopped early for superiority. The companion DigniCap trial reported 66.3 per cent success, also against 0 per cent.
Read the small print
What “success” meant in those trials
The headline numbers are real, but they measure something narrower than most patients assume: keeping at least half your hair, not keeping all of it.
The trialWhat it found
SCALP trial (Nangia et al., JAMA 2017) — Paxman Orbis, 182 women randomisedSuccess defined as keeping more than half your hair and not needing a wig. 48 of 95 cooled patients (50.5%) succeeded; 0 of 47 controls did. All 54 adverse events were mild; headache affected about 12 per cent in the first cycle.
DigniCap pivotal trial (Rugo et al., JAMA 2017) — around 122 patients67 of 101 cooled patients (66.3%) kept at least half their hair, rising to 72 per cent on blinded photographic review; 0 of 16 controls did. Three of 106 stopped because they could not tolerate the cold.
Dutch national registry, 2024 — 7,424 patients, real-world rather than a trialTaxane regimens 78 per cent success; anthracyclines 40 per cent; the two combined 45 per cent. Lower chemotherapy doses correlated with better results.
Pooled evidence — a meta-analysis across 65 trials and more than 5,000 subjectsAn overall success rate of roughly 50 per cent across devices and regimens. The trial investigator's own summary was blunt: scalp cooling is not 100 per cent effective.
Ask this first
Which regimens it suits, and which it does not
This is the question that decides whether scalp cooling is worth your time and money. Ask your oncologist which group your regimen falls into before you commit to anything.
Works moderately
Docetaxel with cyclophosphamide
The common TC regimen: 60.5 per cent success in the FDA-reviewed trial data, across 76 patients.
Works poorly
Anthracycline-based regimens
Doxorubicin or epirubicin combinations such as AC and FEC: 22 to 24 per cent in the US trial analyses, up to 40 per cent in the larger Dutch registry.
Not shown to work
Taxane plus anthracycline together
Where both are given together or in sequence on the same treatment day, both manufacturers' labelling states effectiveness has not been demonstrated. This is a “will not work” exclusion, not a safety one.
Will scalp cooling work on your regimen?
Send us the name of your regimen and we will tell you honestly which of the four groups above it falls into, what the published success rate is, and whether it is available near you.
Free second opinion
Same-week appointments
Ask about your own treatment
An oncology nurse calls you back, usually the same working day.
What it is actually like
What a cooling session involves
It is not complicated, but it is long, and knowing the shape of a session in advance is most of what makes it bearable.
Cap on, 30 to 50 minutes before
Cooling constricts the scalp vessels and cuts blood flow to roughly a fifth to two-fifths of normal, which limits how much drug reaches the follicle. Paxman targets a scalp temperature of 18 to 22°C.
Cap stays on through the infusion
Cold also slows the metabolism of the rapidly dividing hair-matrix cells, making them less vulnerable to cycle-specific drugs such as taxanes.
Cap stays on 20 to 90 minutes after
Longer for drugs with a longer half-life — some protocols keep it on for several hours. Your unit will tell you which applies.
Expect one to two and a half extra hours per cycle
The commonest complaints are headache, chills and scalp discomfort, reported by around 30 to 50 per cent of users and usually settling within 10 to 15 minutes. Between 3 and 12 per cent stop because of the cold.
Any one of these rules it out
Who scalp cooling is not for
These come straight from the two manufacturers' FDA-cleared labelling and from clinical guidance. Meeting any one of them means scalp cooling is off the table — your oncologist will check this before anything else.
- Cold-sensitivity conditions
Cold agglutinin disease, cryoglobulinaemia, cryofibrinogenaemia, cold urticaria, cold-induced migraine, or a previous cold injury to the scalp.
- Blood cancers treated for cure
Leukaemia and lymphoma are excluded on both device labels and in clinical guidance. This is one of the clearest contraindications.
- Known or suspected scalp or skin involvement
Existing scalp metastases, CNS malignancy, melanoma and other skin cancers, head and neck cancers, and tumours with a high likelihood of in-transit skin spread.
- Radiotherapy to the skull, planned or past
Previous cranial radiation narrows the small vessels and reduces the device's effectiveness; planned skull radiotherapy is excluded outright.
- Myeloablative chemotherapy, or continuous or oral regimens
Bone-marrow-ablative conditioning is contraindicated. Continuous pump infusions and tablet chemotherapy are operationally incompatible — the cooling window cannot match the drug-exposure window.
- Children
Contraindicated on the DigniCap label. Severe liver or kidney disease appears as a contraindication on the Paxman label.
Indicative only
What it costs in India
Scalp cooling is usually paid for out of pocket in India. The only published Indian figure we could source is this one, and it should be treated as indicative.
Indicative per session
₹1,500 – ₹5,000
Published by one multi-city Indian cancer hospital chain that offers scalp cooling, and stated there as generally not covered by insurance. Multiply by your number of cycles for a rough course total.
What this figure is not
Read it as a provider's published range, not a quote
It is one chain's price, not a market rate, and not CION's. We found no government scheme or standard private insurance product in India that covers scalp cooling. Ask your own centre for its figure, whether the machine is available on your treatment days, and whether any part is reimbursable under your cover before you budget for it.
What to expect, and when
What your hair will actually do
These are averages from published studies, not promises. Where a figure varies between sources we have given the range rather than picking one.
- Days 1 to 4 weeks after cycle 1Shedding starts
Most often in the second to fourth week. One multicentre study put the mean at 18 days. Once it begins it can be rapid — complete within three to seven days — or gradual.
- Through treatmentHow much comes out
In a large survey, 99.9 per cent of patients had some hair loss and 94.7 per cent lost more than 80 per cent of their scalp hair. Eyebrows, eyelashes, underarm, leg and sometimes pubic hair can be affected too.
- About 6 weeks after the last cyclePeach fuzz
Fine, soft regrowth appears. Around 13 per cent of patients in that survey saw some regrowth during treatment; roughly 80 per cent only after it finished.
- 3 to 6 months after the last cycleVisible hair, often changed
Regrowth began a mean of 3.3 months after completion. It often comes back curlier, finer or a different shade — the so-called chemo curls. Usually temporary.
- 1 to 2 yearsBack to itself, for most people
Mean wig-wearing time in that survey was 12.5 months; 37 per cent were still wearing one at a year. About 4 per cent had under 30 per cent recovery at two years, and around 30 per cent had 40 to 70 per cent recovery at five.
The honest part
When hair loss is permanent
For a minority of patients hair does not fully come back. It is a small minority, but pretending otherwise is not kindness.
- Docetaxel carries the highest documented risk. A UK retrospective survey at two tertiary cancer centres found persistent alopecia in 23.3 per cent of docetaxel patients against 10.1 per cent of paclitaxel patients.
- Cumulative dose appears to matter. A Spanish study found 35 to 52 per cent of patients receiving more than 400 mg/m² of docetaxel developed grade 1 persistent alopecia, with a further 10 per cent at grade 2.
- Taxanes as a class carry roughly eight times the likelihood of persistent or permanent alopecia compared with other chemotherapy classes.
- There is a genetic component. A variant in the ABCB1 gene has been associated with an odds ratio of 3.79 for developing it, thought to relate to slower docetaxel clearance. Older age has also been associated with higher prevalence.
- It is treatable, not just endurable. Topical minoxidil is widely used; low-dose oral minoxidil is emerging; photobiomodulation and platelet-rich plasma are in active trials.
- Raise it early rather than waiting. If regrowth has stalled six to twelve months after your last cycle, ask for a dermatology referral rather than assuming more time will fix it.
One thing worth hearing before you decide anything
Hair loss is one of the most distressing parts of treatment, and the research says so: in an Indian study of 179 chemotherapy patients, 56.4 per cent rated it the worst side effect of all and 72 per cent said it was affecting their social life. Internationally, up to 14 per cent of women said they would consider declining curative chemotherapy because of it.
If that is where you are, please say so out loud to your oncologist rather than quietly to yourself. There may be a scalp-cooling option, a different scheduling, or a regimen choice that changes the picture — and there are wigs of a quality most people do not expect, some of them free through Indian cancer charities. What there is no good version of is declining treatment that could cure you. Call us on 1800 202 8726 and ask.
Day to day
Looking after your scalp and hair
- Mild shampoo, every two to four days rather than daily.
- No heat styling and no chemical treatments during active treatment — no dye, perms or relaxers.
- Soft brush or wide-tooth comb, and no tight ponytails, clips or braids that pull.
- Satin or silk pillowcase to cut overnight friction and tangling.
- Cover and protect the scalp from the sun — a hat or scarf and sunscreen on exposed skin. This matters year-round in Hyderabad.
- Cutting your hair short before treatment is widely suggested, and makes the transition less abrupt.
- Shaving versus letting it fall is a personal choice in every source we checked. No guidance says one is medically necessary.
- Be cautious with eyelash serums. Bimatoprost was only studied in patients who had already finished chemotherapy four to sixteen weeks earlier. There is no safety or efficacy data for using it during active treatment.
- Free and subsidised wigs exist in India. Several charities run wig programmes distributing human-hair wigs through partner hospitals. Ask your team to point you at one.
Clearing the decks
Four myths worth dropping
What you will be toldWhat the evidence says
“Shaving your head makes it grow back thicker.”An optical illusion. Shaving cuts the dead shaft at its thicker base, so regrowth looks and feels coarser. The follicle is unchanged, and shaving cannot alter how thick regrowth is.
“Cold caps make the cancer spread to the scalp.”Not supported. Independent reviews spanning thousands of patients found no meaningful increase in scalp metastases and no survival penalty. Cancer Research UK calls the risk very small.
“If you are not losing hair, the chemo is not working.”False, in both directions. Hair loss reflects a drug's effect on fast-dividing follicle cells, not its effect on your tumour. Response is judged on scans and blood tests.
“There is a tablet or oil that prevents it.”There is not. Minoxidil did not prevent hair loss in a randomised trial, though it shortened the bald period by about 50 days. High-dose vitamin E failed outright against doxorubicin. Calcitriol has only small early-phase data.
I have never once thought less of a patient for minding about their hair. What I mind about is someone turning down a curative treatment without telling me that hair is the reason.Dr. Naresh Gundu, Consultant Medical Oncologist, CION Cancer Clinics
Who reviews this page
The oncologist behind this advice
Dr. Naresh Gundu
Consultant Medical Oncologist, CION Cancer Clinics
MBBS, DNB, DM (Medical Oncology)
Dr. Gundu treats solid tumours with chemotherapy, targeted therapy and immunotherapy, and reviews CION's patient information on systemic treatment.
The CION oncology panel
- 6
- medical oncologists — chemotherapy, targeted therapy, immunotherapy
- 7
- surgical oncologists
- 3
- radiation oncologists
- 150+
- years of combined experience
Female specialists practise in all three oncology disciplines. Ask the helpline if you would prefer to see a woman oncologist.
Want to know whether cooling is worth it on your regimen?
Leave a number and a CION oncology nurse will call you back with the published success rate for your drugs, and what is available near you.
In patients' own words
Patient stories
Every CION patient story is a filmed interview, not a written quote. We do not publish testimonials we cannot show you on camera.
Where to come
CION centres near you
One helpline serves every branch — there are no separate numbers to hunt for.
Ameerpet
Day-care chemotherapy, consultations and blood work
Kukatpally
Day-care chemotherapy, consultations and blood work
L.B. Nagar
Day-care chemotherapy, consultations and blood work
Tolichowki
Day-care chemotherapy, consultations and blood work
Masab Tank
Day-care chemotherapy, consultations and blood work
Banjara Hills
Day-care chemotherapy, consultations and blood work
Kompally
Day-care chemotherapy, consultations and blood work
Balanagar
Day-care chemotherapy, consultations and blood work
Siddipet
Day-care chemotherapy, consultations and blood work
Sangareddy
Day-care chemotherapy, consultations and blood work
Head office: Road No 1, Plot No. 573/I, 1st Floor, Park View Building, Jubilee Hills, Hyderabad 500033. Helpline 1800 202 8726, open 24/7; clinics 9:30 AM–6 PM Monday to Saturday.
The questions patients actually ask
Frequently asked questions
Can chemotherapy hair loss be completely prevented?
No. Scalp cooling is the only method with randomised-trial evidence behind it, and even in its best trial about a third of cooled patients still lost more than half their hair.
It is worth being clear about what “success” meant in those trials: keeping at least half your hair and not needing a wig. That is a real difference to most patients, but it is not the same as keeping your hair.
Does scalp cooling work equally well for every chemotherapy regimen?
No, and this is the single most important thing to ask. It works best with taxane-based regimens — 63 to 83 per cent success in the pivotal trials — and poorly with anthracycline-based regimens, reported at 22 to 24 per cent in the US trial analyses and up to 40 per cent in a larger Dutch real-world registry.
Where a taxane and an anthracycline are given together or in sequence on the same day, both device manufacturers' labelling states it has not been shown to work.
Is scalp cooling safe? Could cancer survive in the scalp?
The evidence does not support that fear. A review covering 1,593 patients across six studies found scalp metastases in 0.6 per cent, none of them as the first or only site of spread. Paxman's own safety data shows 0.61 per cent in cooled patients against 0.41 per cent in uncooled — not a statistically significant difference. A review of over 50,000 patients found roughly 1 per cent either way.
Cancer Research UK describes the risk as very small. It remains contraindicated where scalp or skin involvement is already a known risk — see the list above.
How much does scalp cooling cost in India?
One Indian hospital chain publishes a range of ₹1,500 to ₹5,000 per session and states that it is generally not covered by insurance. We could not find any government or standard private insurance scheme in India that covers it.
For context, automated systems in the US are typically quoted at around ₹1.7 to 2.6 lakh equivalent for a full course. Ask your own centre for its figure before you plan around it.
When will my hair start growing back?
In a large multicentre survey, regrowth began a mean of about 3.3 months after the last cycle, and roughly 80 per cent of patients saw it only after treatment finished. Fine “peach fuzz” tends to appear around six weeks, with fuller hair by three to six months.
Recovery is not always complete. In that same survey about 4 per cent of patients had less than 30 per cent recovery two years on, and around 30 per cent had 40 to 70 per cent recovery at five years.
Why did my hair grow back curly, or a different colour?
Chemotherapy can linger in the follicle and disrupt how the hair shaft is formed, which changes texture and sometimes colour. MD Anderson is candid that the biology of the colour change is not fully understood.
It is usually temporary. As one of their dermatologists puts it, time is your best friend — the further you get from chemotherapy, the more the hair returns to its own texture and colour.
Can minoxidil prevent chemotherapy hair loss?
No. A double-blind randomised trial found topical 2 per cent minoxidil did not prevent hair loss. What it did do was shorten the bald period — 87 days against 137 in the placebo group, a difference of about 50 days.
Vitamin E at high dose was tested against doxorubicin-induced hair loss and failed. Calcitriol and AS101 have only small early-phase data. None of them is a substitute for scalp cooling.
Does hair loss mean the chemotherapy is working?
No, and the reverse is equally untrue. Hair loss happens because chemotherapy also affects other fast-dividing healthy cells. Whether a particular drug and dose causes it depends on the drug's properties, not on how the tumour is responding.
Whether treatment is working is judged on scans and blood tests. Your hair tells you nothing about it either way.
Read next
Questions to ask about your chemotherapy drugs43 questions, grouped and ready to copy to your phoneCan you stop chemotherapy midway?Your right to stop, and what it costs depending on why you are treatedHow much water should you drink during chemotherapy?The fluid target, and the days it matters most
Next step
Ask us what is realistic for your treatment
We will tell you what the published evidence says about your regimen rather than what you would like to hear. A second opinion on an existing plan is free, and you keep your current doctor.
Free second opinion on an existing plan
Aarogyasri, CGHS, ECHS & cashless insurance
Request a call back
Tell us what you need and an oncology nurse will call you.
Sources
- Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer (SCALP trial) — Nangia J et al., JAMA 2017
- DEN150010 de novo classification review, DigniCap scalp cooling system — US Food and Drug Administration
- FDA clears expanded use of cooling cap to reduce hair loss during chemotherapy — US Food and Drug Administration
- Cancer Currents — FDA clearance of cooling caps for chemotherapy — National Cancer Institute
- Has scalp cooling reached the level of standard of care? — The ASCO Post
- Scalp cooling — Dutch registry outcomes and current coverage — Living Beyond Breast Cancer
- Contraindications — DigniCap (Dignitana)
- US safety information — Paxman Scalp Cooling
- Scalp cooling does not pose a risk for scalp metastases — ecancer
- Treatments to prevent hair loss, and cold caps — Cancer Research UK
- Managing hair loss with scalp cooling — Memorial Sloan Kettering Cancer Center
- Review of agents studied for prevention of chemotherapy-induced alopecia — Current Oncology (MDPI)
- Persistent chemotherapy-induced alopecia and docetaxel — Current Oncology (MDPI)
- Multicentre survey of chemotherapy-induced alopecia — onset, regrowth and recovery — PLOS ONE
- What are chemo curls? Understanding post-chemo hair changes — MD Anderson Cancer Center
- A descriptive study to analyse chemotherapy-induced hair loss and its impact — Indian Dermatology Online Journal 2019
- Scalp cooling technology — published Indian per-session price range — HCG Oncology
- Does shaving make hair grow back thicker? — Cleveland Clinic
- Safety and efficacy of bimatoprost for eyelash growth in post-chemotherapy subjects — Journal of Clinical and Aesthetic Dermatology
General information, not a prescription. This page explains what is generally true for people having chemotherapy. It is not advice about your own treatment, and nothing on it should be used to start, stop or change a medicine. Your own oncology team knows your diagnosis, your drugs, your blood results and your other conditions — we do not. If anything here worries you, or anything about your treatment feels wrong, call your team on 1800 202 8726. The helpline is answered 24 hours a day.